Management and Board of Directors

 

Donald W. Grimm
Executive Chairman

Mr. Grimm has served as a Director with Hamilton Bioventures since August 2001. Since June 1995 he has served as Chairman and President of Strategic Design LLC, a strategic planning and consulting company. Mr. Grimm retired from Eli Lilly & Company, a research-based pharmaceutical company, in December 1993 after 23 years of service. Mr. Grimm held positions at Eli Lilly as Director of Worldwide Pharmaceutical Pricing, Director of Pharmaceutical Market Research, and Director of Sales. Following these assignments, Mr. Grimm was President & Chief Executive Officer of Hybritech, Inc., a wholly owned subsidiary of Lilly. In addition, he is currently a Director of several private and public companies, including Life Technologies Corp., Angstrom, CellzDirect, HTG and ACS. Mr. Grimm received his B.S. in Pharmacy and his M.B.A. from the University of Pittsburgh.

Cam L. Garner
Director

Mr. Garner is a pharmaceutical executive with diverse experience in the healthcare industry ranging from diagnostics and devices to pharmaceuticals. Mr. Garner was Chief Executive Officer of Dura Pharmaceuticals, Inc. from 1989-1995 and Chairman and CEO from 1995-2000. Dura was sold to Elan in November 2000, for $1.8 billion. Mr. Garner has co-founded specialty pharmaceutical companies Cadence Pharmaceuticals, Inc., Somaxon Pharmaceuticals, Verus Pharmaceuticals, Inc., Evoke Pharma, Zogenix, Inc., Elevation Pharmaceuticals, Meritage Pharma, Xcel Pharmaceuticals, Inc. and DJ Pharma. He serves as Chairman of Cadence, Evoke, Meritage, Zogenix and Elevation. Xcel Pharmaceuticals was sold in March, 2005 to Valeant International and DJ Pharma was sold to Biovail in 2000. Mr. Garner earned a Master’s Degree in Business Administration from Baldwin-Wallace College in Berea, Ohio, and a Bachelor of Arts Degree in Biology from Virginia Wesleyan.

Edward T. Maggio, Ph.D.,
Chief Executive Officer and Director

Prior to co-founding Aegis, Dr. Maggio was founder and Chief Executive Officer of Structural Bioinformatics Inc., (major corporate investors IBM and Quest Diagnostics). He was founder and Chief Executive Officer of ImmunoPharmaceutics, Inc., which developed a number of endothelin antagonists, including Pfizer’s Thelin® (Sitaxsentan), approved in 2006 for sale in Europe for cardiovascular disease. Dr. Maggio has been a founder and board member or chairperson of seven public and private life science companies in the San Diego area and one in Copenhagen, Denmark. He received his Ph.D. from the University of Michigan and was an NIH postdoctoral fellow at the University of California, San Francisco (UCSF) Department of Pharmaceutical Chemistry. He was the keynote speaker at the Washington, DC  celebration of “The 25th Anniversary of the Institute of General Medical Sciences, NIH”. He has served or currently serves as an advisory board member for the Polytechnic Institute of New York University, Department of Chemical and Biological Sciences; the University of California, San Diego, Dean’s Board of Advisors for Biological Sciences; the Baylor University School of Engineering and Computer Science; the California State University, San Marcos, Biotechnology Programs Advisory Board; and the Industry Council of the San Diego Consortium for Regenerative Medicine; the Editorial Board of the “Journal of Excipients and Food Chemicals”, and a reviewer for the journal “Diabetes, Obesity and Metabolism.” Dr. Maggio has edited and coauthored a number of books and scientific articles in the biotechnology, biotherapeutics, structural bioinformatics, small molecule and peptide/protein pharmaceutics, and immunodiagnostics areas and is an author of more than eighty issued and pending U.S. and foreign patents.

Ralph R. Barry
Chief Business Officer and Director

Prior to co-founding Aegis, from February 1998 through April 2003, Mr. Barry served as Vice President and Chief Financial Officer and Secretary of Structural Bioinformatics, Inc. (“SBI”). Prior to joining SBI, Mr. Barry served as Vice President, Chief Financial Officer and Secretary of Imaging Technologies Corporation (Nasdaq: ITEC), a leader in the development of laser printer and imaging technologies. Mr. Barry joined ITEC as Controller and Chief Accounting Officer in October 1993, and became its Chief Financial Officer and Secretary in August 1995 and its Vice President of Finance in December 1996.  Mr. Barry served in the Washington, D.C., and San Diego offices of Price Waterhouse, LLP from August 1989 through October 1993. Mr. Barry received a B.S. in accounting from the University of Maryland and is a non-practicing CPA.

Since 2003, Mr. Barry has served on the Board of Management for the San Diego YMCA Overnight Camping Branch holding a number of key leadership positions including three years as Board Chairman. During the 2012 YMCA of San Diego County Annual Meeting, Mr. Barry was a recipient of the Golden Triangle of Distinguished Service Award, the Y’s highest award for volunteer service.

Alfred G. Ferris
Director

Mr. Ferris, the senior founding principal and president of Ferris & Britton, PC, a law firm devoted to corporate and corporate securities practice, was admitted to the California Bar in 1964. He is recognized for his expertise in the corporate securities, high-technology, biotechnology, cable television and labor (management) areas of corporate practice. Mr. Ferris is a member of the California, American and San Diego Bar Associations and has served as chairman and member of several California State Bar committees and boards. He is on the National Panel of Arbitrators of the American Arbitration Association and has served as adjunct professor of law at the University of San Diego School of Law. He received his undergraduate and law degrees from Stanford University.